New hope for kids with Tough-to-Treat cancer: doubling down on a key drug

This study is testing if using a stronger chemotherapy schedule and giving a targeted drug called rituximab more often and earlier in treatment can help children and teenagers with very aggressive forms of B-cell lymphoma live longer without their cancer coming back. It builds on a previous successful treatment by giving more doses of rituximab and adjusting the chemotherapy, especially for the highest-risk patients. The goal is to improve survival rates compared to the older treatment plan.